ClinicalTrials.gg
RecruitingNCT07519811oncOPALUpdated Apr 16, 2026

LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)

An interventional study of LLM-Generated Plain-Language Patient Synopsis in Hematologic Neoplasms and Oncologic Disorders, sponsored by Technical University of Munich. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Technical University of Munich · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.

Planned enrollment
17th of 50
150 · median 91
Started
2026
with 3 others
No phase
5 of 65
2 open now
Primary completion
2026-12
later than 6 of 27 live
Registered
63rd of 65
by date
Lead sponsor
3 of 65
Technical University of Munich

Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 17th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2026, is one of 5 with no phase, reaches primary completion later than 6 of the 27 other live ones, and was the 63rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Hematologic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This study tests whether patients with blood cancer or other cancers better understand their medical information when it is rewritten in plain language by an artificial intelligence (AI) system.

When patients are discharged from the hospital, they receive a medical letter summarizing their diagnosis, treatment, and next steps. These letters are often written in technical language that is difficult for patients to understand. In this study, an AI language model running on the hospital's own secure servers rewrites parts of this letter into simpler language. A physician checks the simplified version before the patient receives it.

Patients are randomly assigned to one of two groups. One group receives both the standard medical letter and the AI-simplified version. The other group receives the standard letter only. A separate group of patients who do not speak German well will receive a simplified and translated version.

After reading their letter, all participants fill out a short questionnaire about how well they understood the information. The study takes place at TUM University Hospital (Klinikum rechts der Isar) in Munich, Germany.

Read the detailed description

Background:

Studies show that up to 40-80% of medical information conveyed during physician consultations is not correctly recalled or understood by patients. This problem is particularly relevant in hematology and oncology, where treatment regimens, prognoses, and side-effect profiles are complex. Large language models (LLMs) have demonstrated the ability to convert medical texts into plain language with high accuracy. However, prospective randomized controlled trials evaluating the clinical benefit of LLM-simplified patient synopses in routine care are lacking.

Study Design:

Prospective, single-center, randomized controlled trial with parallel group design. Randomization is 2:1 (intervention : control) using permuted blocks of variable size (4-6). An additional non-randomized translation arm enrolls patients with insufficient German language proficiency.

Intervention:

The locally implemented LLM system (on-premise, no external data transmission) automatically simplifies the following sections of the discharge letter: Current Status, Medical History, Epicrisis, and Further Management. A study physician reviews and approves the simplified version before it is given to the patient. The system is not classified as a medical device and is not used for diagnosis or treatment decisions.

Endpoints:

The primary endpoint is a comprehension score measured by a 5-item scale (10-point Likert, based on PEMAT), assessing overall comprehension and comprehension of diagnosis, treatment, next steps, and medical terminology. Secondary endpoints include patient satisfaction (EORTC QLQ-INFO25 subscales), subjective uncertainty reduction, format preference, physician review time, correction rate, and translation quality.

Statistical Analysis:

The primary endpoint will be analyzed using a t-test or Mann-Whitney U-test. A clinically relevant difference of 1.5 points on the 10-point scale is assumed. With a standard deviation of 2.5, power of 80%, and alpha of 0.05 (two-sided), 136 randomized patients are required (91 intervention, 45 control). Accounting for a 10% dropout rate, 150 patients will be recruited for the randomized arms, plus 30 for the translation arm (total n=180).

Data Protection:

All data are pseudonymized and stored on secure hospital servers. No patient data are transmitted to external servers or cloud services. The study complies with GDPR.

03

Conditions studied

  • Hematologic Neoplasms
  • Oncologic Disorders

Keywords

  • Patient-Provider Communication
  • Patient Health Literacy
  • Large Language Model
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Inpatient of the Department of Medicine III (Hematology/Oncology) at TUM University Hospital (Klinikum rechts der Isar), Munich, Germany
  • Receipt of a discharge letter including the sections Current Status, Medical History, Epicrisis, and Further Management as part of routine clinical care
  • Capacity to provide
  • Written informed consent following the consent procedure

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment precluding independent assessment of comprehension (e.g., dementia, severe encephalopathy)
  • Participation in another study with potential influence on the study endpoints
  • Lack of capacity to provide
  • Refusal to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Intervention: LLM-Simplified Synopsis

    Participants receive the standard discharge letter synopsis plus an LLM-generated plain-language version of the following sections: Current Status, Medical History, Epicrisis, and Further Management. The simplified version is reviewed and approved by a study physician before being given to the patient.

    Other: LLM-Generated Plain-Language Patient Synopsis

  • No intervention
    Control: Standard Synopsis

    Participants receive the standard discharge letter synopsis only, as provided in routine clinical care.

Interventions

  • OtherLLM-Generated Plain-Language Patient Synopsis

    A locally implemented large language model (GPT-OSS, on-premise) automatically rewrites selected sections of the hospital discharge letter (Current Status, Medical History, Epicrisis, and Further Management) into plain language. A study physician reviews the output for accuracy before it is provided to the patient. The system is not classified as a medical device and is not used for diagnosis or treatment decisions. No patient data are transmitted to external servers.

06

What researchers measure

Primary outcomes

  1. Patient Comprehension Score

    Comprehension of the patient synopsis measured using a 5-item scale based on the Patient Education Materials Assessment Tool (PEMAT; scores range from 1 to 10, with higher scores indicating better comprehension), assessing overall comprehension and comprehension of diagnosis, treatment, next steps, and medical terminology. The score is calculated as the mean of all five items (range 0-10; higher scores indicate better comprehension).

    Time frame: At the time of hospital discharge (Day 0), assessed immediately after reading the synopsis (approximately 15-30 minutes after receipt)

Secondary outcomes

  1. Patient Satisfaction with Information Received

    Patient satisfaction (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information Module 25 \[EORTC QLQ-INFO25\] subscales; scores range from 0 to 100, with higher scores indicating better-perceived information)

    Time frame: Day 0, assessed immediately after reading the synopsis

  2. Subjective Uncertainty Reduction

    Single-item measure on a 0-10 scale, administered before and after reading the synopsis

    Time frame: Day 0, before and after reading the synopsis

  3. Patient Preference for Synopsis Format

    Categorical variable assessing which synopsis format the patient preferred

    Time frame: Day 0, assessed immediately after reading the synopsis

  4. Physician Review Time

    Time in minutes required for the study physician to review and approve the LLM-generated synopsis

    Time frame: Day 0, recorded at time of physician review

  5. Physician Correction Rate

    Rate of necessary corrections made by the study physician to the LLM-generated synopsis prior to patient handout

    Time frame: Day 0, recorded at time of physician review

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared. All study data are pseudonymized and stored on secure hospital servers at TUM University Hospital (Klinikum rechts der Isar) in compliance with the General Data Protection Regulation (GDPR). The study protocol does not provide for disclosure of participant-level data to third parties. Aggregate, anonymized data will be made available through publication of results.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 8 months is below that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2026
First posted
Apr 9, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 1, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519811
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Krischan Braitsch, MD
Contact
krischan.braitsch@tum.de
+49 089 4140 1268
Lisa C. Adams, MD
Contact
lisa.adams@tum.de
+49 089 4140 1084

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion